For Biogenera, the PIP is not merely a regulatory requirement; it is a central component for structuring the pediatric clinical development of BGA002 and strengthening its strategic value.
In the development of a new drug, certain steps often remain hidden from the general public despite having a decisive impact on the program's future. One of these is the Pediatric Investigation Plan (PIP): a plan that every pharmaceutical company is required to submit to the European Medicines Agency (EMA) when their drug could potentially be used in the pediatric population.Established by Regulation (EC) No 1901/2006 and evaluated by the EMA’s Paediatric Committee (PDCO), the PIP details how the company intends to study the drug in children—specifying which studies will be conducted, their objectives, timelines, and any necessary adaptations to the formulation.
Why the PIP is Particularly Relevant for BGA002
In the case of BGA002, the anti-tumor drug developed by Biogenera, the pediatric dimension is not a secondary extension; it is the heart of the program. The cancers targeted by BGA002—neuroblastoma and rhabdomyosarcoma—primarily affect children and adolescents, and available therapeutic options remain limited. The PIP, therefore, is not a formal obligation to be fulfilled on the sidelines of development. Instead, it serves as the regulatory translation of a clinical direction already inherent to the nature of the target diseases.
The PIP in the BGA002 Roadmap
The submission of the PIP is scheduled between the end of Q2 and the beginning of Q3 2026. It follows a well-defined sequence: After the completion of drug production according to GMP (Good Manufacturing Practice) standards. Before the submission of the dossier to launch the Phase I clinical trial, which is expected in Q1 2027. This timing allows Biogenera to engage with the PDCO ahead of the trial, ensuring the European regulatory path remains aligned with the program's clinical progress.
Strategic Value: Market Exclusivity and Credibility
The PIP also carries significant strategic weight: - Regulatory Incentives: For drugs with Orphan Drug Designation—a status already granted to BGA002 by both the EMA and the FDA—the successful completion of a PIP can extend market exclusivity by two years beyond the standard ten, significantly boosting future commercial protection.
- External Credibility: Submitting the PIP signals to investors, potential partners, and institutional stakeholders that BGA002 is progressing through a structured framework with clear scientific and regulatory vision. Essentially, it demonstrates that Biogenera is rigorously building the path toward clinical trials and, ultimately, the market.
In Summary
With the planned submission of the PIP in 2026, Biogenera is taking a concrete step in the development of BGA002. It is not just a bureaucratic task, but a lever to consolidate the program, access regulatory incentives, and reinforce the long-term value of its therapeutic candidate.
English 
Italian